Merit Medical Systems (MMSI)
Market Price (8/12/2026): $91.13 | Market Cap: $5.4 BilSector: Health Care | Industry: Health Care Supplies
Merit Medical Systems (MMSI)
Market Price (8/12/2026): $91.13Market Cap: $5.4 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% Low stock price volatilityVol 12M is 31% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Trading close to highsDist 52W High is -2.2% Weak multi-year price returns2Y Excs Rtn is -46%, 3Y Excs Rtn is -46% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 24x, P/EPrice/Earnings or Price/(Net Income) is 37x Key risksMMSI key risks include [1] regulatory compliance challenges, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Low stock price volatilityVol 12M is 31% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Trading close to highsDist 52W High is -2.2% |
| Weak multi-year price returns2Y Excs Rtn is -46%, 3Y Excs Rtn is -46% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 24x, P/EPrice/Earnings or Price/(Net Income) is 37x |
| Key risksMMSI key risks include [1] regulatory compliance challenges, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Merit Medical Systems (MMSI) stock has gained about 35% since 4/30/2026 because of the following key factors:
1. Strong Financial Performance and Upbeat Guidance. Merit Medical Systems significantly surpassed analyst expectations for both fiscal Q1 2026 (announced April 30, 2026) and fiscal Q2 2026 (announced July 30, 2026) earnings. For fiscal Q2 2026, adjusted earnings per share (EPS) reached $1.19, beating the consensus estimate of $0.96 by 23.9%, and revenue grew 9.5% year over year to $418.8 million, surpassing the consensus by 3.5%. This strong performance led the company to raise its full-year 2026 revenue guidance to $1.631 billion–$1.643 billion and adjusted EPS guidance to $4.25–$4.35, representing an 11%-14% increase.
2. Improved Profitability and Operating Leverage. The company demonstrated enhanced profitability, with its gross profit margin improving to 51.4% in fiscal Q2 2026, up from 48.2% in the prior-year quarter, and a non-GAAP operating margin reaching 22.6%. This indicates stronger operating leverage and efficient management, contributing to increased investor confidence.
Show more
Merit Medical Systems (MMSI) stock has gained about 35% since 4/30/2026 because of the following key factors:
1. Strong Financial Performance and Upbeat Guidance. Merit Medical Systems significantly surpassed analyst expectations for both fiscal Q1 2026 (announced April 30, 2026) and fiscal Q2 2026 (announced July 30, 2026) earnings. For fiscal Q2 2026, adjusted earnings per share (EPS) reached $1.19, beating the consensus estimate of $0.96 by 23.9%, and revenue grew 9.5% year over year to $418.8 million, surpassing the consensus by 3.5%. This strong performance led the company to raise its full-year 2026 revenue guidance to $1.631 billion–$1.643 billion and adjusted EPS guidance to $4.25–$4.35, representing an 11%-14% increase.
2. Improved Profitability and Operating Leverage. The company demonstrated enhanced profitability, with its gross profit margin improving to 51.4% in fiscal Q2 2026, up from 48.2% in the prior-year quarter, and a non-GAAP operating margin reaching 22.6%. This indicates stronger operating leverage and efficient management, contributing to increased investor confidence.
3. Strategic Acquisitions Driving Growth. Merit Medical Systems completed the acquisition of View Point Medical for $137.3 million net of cash on April 1, 2026, which added the OneMark Detection Imaging System. This acquisition, along with earlier strategic deals, is expected to be a new growth driver, complementing existing product lines and contributing to the company's strong financial outlook.
4. Positive Analyst Sentiment and Increased Price Targets. Analysts have maintained a "Moderate Buy" consensus rating for MMSI, with 8 out of 11 covering firms recommending a "Buy" as of August 7, 2026. Following the strong fiscal Q2 2026 results and raised guidance, several analysts increased their price targets, with the average 12-month price target reaching $100.30, indicating a potential upside of 13.45% from the stock's price on August 7, 2026.
Show less
Stock Movement Drivers
Fundamental Drivers
The 33.6% change in MMSI stock from 4/30/2026 to 8/11/2026 was primarily driven by a 28.3% change in the company's P/E Multiple.| (LTM values as of) | 4302026 | 8112026 | Change |
|---|---|---|---|
| Stock Price ($) | 68.18 | 91.11 | 33.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,542 | 1,579 | 2.4% |
| Net Income Margin (%) | 9.0% | 9.2% | 2.1% |
| P/E Multiple | 29.1 | 37.4 | 28.3% |
| Shares Outstanding (Mil) | 60 | 60 | -0.3% |
| Cumulative Contribution | 33.6% |
Market Drivers
4/30/2026 to 8/11/2026| Return | Correlation | |
|---|---|---|
| MMSI | 33.6% | |
| Market (SPY) | 7.2% | -0.9% |
| Sector (XLV) | 15.1% | 39.9% |
Fundamental Drivers
The 12.4% change in MMSI stock from 1/31/2026 to 8/11/2026 was primarily driven by a 15.0% change in the company's Net Income Margin (%).| (LTM values as of) | 1312026 | 8112026 | Change |
|---|---|---|---|
| Stock Price ($) | 81.09 | 91.11 | 12.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,477 | 1,579 | 6.9% |
| Net Income Margin (%) | 8.0% | 9.2% | 15.0% |
| P/E Multiple | 40.6 | 37.4 | -7.9% |
| Shares Outstanding (Mil) | 59 | 60 | -0.7% |
| Cumulative Contribution | 12.4% |
Market Drivers
1/31/2026 to 8/11/2026| Return | Correlation | |
|---|---|---|
| MMSI | 12.4% | |
| Market (SPY) | 11.7% | 20.4% |
| Sector (XLV) | 9.0% | 44.6% |
Fundamental Drivers
The 7.4% change in MMSI stock from 7/31/2025 to 8/11/2026 was primarily driven by a 10.9% change in the company's Net Income Margin (%).| (LTM values as of) | 7312025 | 8112026 | Change |
|---|---|---|---|
| Stock Price ($) | 84.86 | 91.11 | 7.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,433 | 1,579 | 10.2% |
| Net Income Margin (%) | 8.3% | 9.2% | 10.9% |
| P/E Multiple | 42.1 | 37.4 | -11.3% |
| Shares Outstanding (Mil) | 59 | 60 | -0.9% |
| Cumulative Contribution | 7.4% |
Market Drivers
7/31/2025 to 8/11/2026| Return | Correlation | |
|---|---|---|
| MMSI | 7.4% | |
| Market (SPY) | 22.9% | 20.2% |
| Sector (XLV) | 30.5% | 43.3% |
Fundamental Drivers
The 22.0% change in MMSI stock from 7/31/2023 to 8/11/2026 was primarily driven by a 31.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312023 | 8112026 | Change |
|---|---|---|---|
| Stock Price ($) | 74.67 | 91.11 | 22.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,198 | 1,579 | 31.8% |
| Net Income Margin (%) | 7.5% | 9.2% | 23.3% |
| P/E Multiple | 47.9 | 37.4 | -22.1% |
| Shares Outstanding (Mil) | 58 | 60 | -3.6% |
| Cumulative Contribution | 22.0% |
Market Drivers
7/31/2023 to 8/11/2026| Return | Correlation | |
|---|---|---|
| MMSI | 22.0% | |
| Market (SPY) | 74.3% | 38.1% |
| Sector (XLV) | 31.1% | 41.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MMSI Return | 12% | 13% | 8% | 27% | -9% | 2% | 62% |
| Peers Return | 20% | -22% | -1% | 10% | 11% | -6% | 5% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| MMSI Win Rate | 58% | 50% | 67% | 50% | 50% | 38% | |
| Peers Win Rate | 48% | 43% | 47% | 58% | 60% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MMSI Max Drawdown | -19% | -27% | -26% | -13% | -28% | -35% | |
| Peers Max Drawdown | -23% | -39% | -30% | -21% | -24% | -33% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, ABT, BSX, TFX, ANGO. See MMSI Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/11/2026 (YTD)
How Low Can It Go
| Event | MMSI | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -22.8% | -9.5% |
| % Gain to Breakeven | 29.6% | 10.5% |
| Time to Breakeven | 215 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -19.0% | -24.5% |
| % Gain to Breakeven | 23.5% | 32.4% |
| Time to Breakeven | 107 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -36.8% | -33.7% |
| % Gain to Breakeven | 58.1% | 50.9% |
| Time to Breakeven | 44 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -23.9% | -19.2% |
| % Gain to Breakeven | 31.5% | 23.8% |
| Time to Breakeven | 949 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -14.1% | -3.7% |
| % Gain to Breakeven | 16.4% | 3.9% |
| Time to Breakeven | 21 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -36.2% | -12.2% |
| % Gain to Breakeven | 56.8% | 13.9% |
| Time to Breakeven | 215 days | 62 days |
In The Past
Merit Medical Systems's stock fell -3.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 3.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MMSI | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -22.8% | -9.5% |
| % Gain to Breakeven | 29.6% | 10.5% |
| Time to Breakeven | 215 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -36.8% | -33.7% |
| % Gain to Breakeven | 58.1% | 50.9% |
| Time to Breakeven | 44 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -23.9% | -19.2% |
| % Gain to Breakeven | 31.5% | 23.8% |
| Time to Breakeven | 949 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -36.2% | -12.2% |
| % Gain to Breakeven | 56.8% | 13.9% |
| Time to Breakeven | 215 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -27.9% | -17.9% |
| % Gain to Breakeven | 38.6% | 21.8% |
| Time to Breakeven | 1176 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -36.3% | -53.4% |
| % Gain to Breakeven | 57.0% | 114.4% |
| Time to Breakeven | 51 days | 1085 days |
In The Past
Merit Medical Systems's stock fell -3.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 3.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Merit Medical Systems (MMSI)
Merit Medical Systems, Inc. (MMSI) is a medical device company that specializes in designing, developing, manufacturing, and marketing single-use medical products. These products are integral to interventional, diagnostic, and therapeutic procedures, primarily serving critical medical specialties such as cardiology, radiology, oncology, critical care, and endoscopy. The company structures its operations into two main segments: Cardiovascular and Endoscopy.
The company's diverse product portfolio includes a wide array of specialized devices. For cardiovascular applications, Merit Medical provides solutions for both peripheral and cardiac interventions, encompassing angiography, electrophysiology, fluid management, hemodynamic monitoring, and hemostasis. Within its endoscopy segment, it offers pulmonary products like tracheobronchial stents and dilation balloons, as well as gastroenterology products and various kits and accessories for endoscopic and bronchoscopic procedures. Additionally, Merit Medical supplies custom procedural solutions such as critical care products, specialized syringes, manifold kits, and pre-packaged trays, alongside component products like coated tubes and wires.
Merit Medical primarily targets healthcare providers as its customers, selling its products to hospitals and to physicians, technicians, and nurses practicing in alternate care settings. The company employs a comprehensive sales strategy, distributing its products through a direct sales force, third-party distributors, original equipment manufacturer (OEM) partners, and custom procedure tray manufacturers. Its market presence is global, serving customers both within the United States and internationally.
AI Analysis | Feedback
A specialized Medtronic for single-use medical tools.
The Johnson & Johnson of interventional medical consumables.
Like Becton Dickinson (BD) for more advanced interventional and diagnostic kits and devices.
AI Analysis | Feedback
- Peripheral Intervention Products: Medical devices used for the diagnosis and treatment of diseases in peripheral vessels and organs.
- Cardiac Intervention Products: Medical devices designed for various interventional procedures to treat heart conditions, including access, angiography, and hemostasis.
- Custom Procedural Solutions: Tailored kits and systems for critical care, disinfection, and other medical procedures, including syringes, manifold kits, and trays.
- Coated Tubes and Wires: Specialized components used in various medical devices and procedures.
- Sensor Components (MEMS): Microelectromechanical systems components used in medical applications.
- Pulmonary Products: Devices such as tracheobronchial stents, delivery systems, and dilation balloons for endoscopic dilation of strictures.
- Gastroenterology Products: Medical devices specifically for gastroenterology procedures.
- Endoscopy and Bronchoscopy Kits and Accessories: Complementary products and tools for endoscopic and bronchoscopic procedures.
AI Analysis | Feedback
Merit Medical Systems (MMSI) primarily sells its products to other companies and institutions within the healthcare sector. Its major customer categories include:
- Hospitals: Large institutional buyers of medical devices and supplies.
- Distributors: Companies that purchase products from Merit Medical Systems and then resell them to various healthcare providers.
- Original Equipment Manufacturer (OEM) Partners: Other medical device companies that incorporate Merit Medical Systems' components into their own products.
- Custom Procedure Tray (CPT) Manufacturers: Companies that assemble customized kits and trays for medical procedures, often including products from Merit Medical Systems.
- Alternate Site-Based Medical Facilities: Such as clinics, surgical centers, and physician offices, where physicians, technicians, and nurses use Merit Medical Systems' products for patient care.
AI Analysis | Feedback
AI Analysis | Feedback
Martha Aronson, President and Chief Executive Officer
Martha Aronson was appointed President and Chief Executive Officer of Merit Medical Systems, Inc. in October 2025. She possesses extensive experience in global healthcare, having overseen global healthcare businesses with revenues ranging from $500 million to $1 billion. Before joining Merit, Ms. Aronson served as Executive Vice President and President of Global Healthcare for Ecolab, Inc., and previously as Senior Vice President and President – North America for Hill-Rom Holdings, Inc. She also spent nearly two decades at Medtronic, where she held various general management and leadership roles both in the United States and internationally.
Raul Parra, Chief Financial Officer and Treasurer
Raul Parra, CPA, was appointed Merit's Chief Financial Officer and Treasurer in July 2018, having previously served as Interim Chief Financial Officer from May 2018 to July 2018. He also held the positions of Vice President of Accounting and Corporate Controller at Merit. Prior to his tenure at Merit, Mr. Parra was employed as an auditor by Deloitte & Touche LLP from 2003 to 2009. He holds a Bachelor of Science degree in Business Administration with an emphasis in accounting from Sonoma State University and is a certified public accountant. Mr. Parra is also a member of the Board of Directors at American Express National Bank.
Adam Smith, Chief Commercial Officer
Adam Smith joined Merit Medical in 2018 and was appointed Chief Commercial Officer in 2025. In this role, he leads the development and expansion of Merit's global commercial activities.
Brian G. Lloyd, Chief Legal Officer and Corporate Secretary
Brian G. Lloyd was appointed Merit's Chief Legal Officer and Corporate Secretary in April 2016. Before joining Merit, Mr. Lloyd spent more than 20 years as a member of the business transactions group at Parr Brown Gee & Loveless.
Neil Peterson, Chief Operating Officer
Neil Peterson has been with Merit Medical Systems for 27 years, currently serving as Chief Operating Officer.
AI Analysis | Feedback
1. Regulatory Compliance and Healthcare Industry Pressures: The company operates within a highly regulated global environment, subject to stringent oversight by bodies like the FDA and adherence to regulations such as EU MDR, GDPR, and PIPL. Compliance failures can lead to significant penalties, product delays, or market withdrawals. Furthermore, Merit Medical Systems is exposed to intense pressure from the broader healthcare industry, including cost-containment measures and consolidation among healthcare providers. A notable specific risk is China's Volume-Based Procurement (VBP) policy, which aims to reduce medical device prices and has already negatively impacted the company's revenues, with expectations for continued impact.
2. Intense Competition and Technological Advancements: The medical device market is fiercely competitive and characterized by rapid technological innovation. Merit Medical Systems faces challenges from both larger companies with extensive resources and smaller, agile firms with niche offerings. Competitors' integration of advanced technologies, such as artificial intelligence (AI), further intensifies this competitive landscape. The company must continuously invest in research and development and differentiate its products to maintain its market position against the constant threat of new entrants and evolving product alternatives.
3. Supply Chain Disruptions and Cost Volatility: Merit Medical Systems is vulnerable to disruptions in its supply chain, particularly from third-party vendors providing raw materials and components. Geopolitical tensions and conflicts, such as those in the Middle East, Venezuela, and Ukraine, exacerbate these risks, potentially leading to increased costs and production delays. Additionally, the company faces threats to operational stability due to cost volatility in raw materials, especially oil-based components like resins, and in logistics.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Merit Medical Systems (MMSI)
Merit Medical Systems (MMSI) is anticipated to drive future revenue growth over the next 2-3 years through a combination of strategic initiatives, product innovation, and market expansion:
- New Product Launches and Expansion of Therapeutic Portfolio: The company expects significant contributions from recently launched products, with new products accounting for approximately 10% of 2025 revenue growth in the cardiac and peripheral intervention categories. Notably, revenue from the WRAPSODY Cell-Enabled Endovascular System (CIE) is projected to increase from $3 million in 2025 to $7 million in 2026, supported by favorable reimbursement dynamics including the implementation of NTAP and expected Transitional Pass-Through (TPT) status. Other innovative devices like the Prelude SNAP system, Ventrax Delivery System, Prelude radial sheath, and SCOUT radar localization system are also contributing to demand. The company's therapeutic product portfolio, which constitutes one-third of its revenue, is a faster-growing segment with a 19% compound annual growth rate (CAGR).
- Strategic Acquisitions: Acquisitions are expected to provide inorganic revenue contributions of $13 million to $15 million in 2026. Recent acquisitions, such as Biolife Delaware and the C2 CryoBalloon device, have expanded Merit Medical's capabilities in interventional products and added new technology platforms. The company also benefited from the acquisition of lead management products from Cook Medical. Merit continues to emphasize disciplined merger and acquisition (M&A) activities to broaden its product offerings and support overall growth.
- Growth in Cardiovascular and Endoscopy Segments: The cardiovascular segment remains a primary growth engine, experiencing strong performance in cardiac intervention, which saw a 21% increase in sales in Q4 2025, and peripheral intervention, which grew by 13% in the same period. The endoscopy segment also demonstrated robust growth, with a 15% year-over-year increase in revenue for Q4 2025. Management anticipates continued growth in 2026, driven by an increase in cardiovascular procedure volumes globally.
- International Expansion and Market Diversification: Merit Medical benefits from a globally diversified revenue base, with approximately 40% of its revenue derived from international customers. For 2026, the company projects U.S. revenue growth of 6% to 7% and international revenue growth of 5% to 6%, indicating a continued focus on expanding its global footprint.
- Continued Growth Initiatives (CGI) Program and Optimized Product Mix: The company's "Continued Growth Initiatives" Program, with targets set through December 31, 2026, aims for a total revenue increase at an organic, constant currency CAGR of 5% to 7%. This program includes a focus on improving product mix, optimizing geographic presence, and strategic pricing, alongside SKU rationalization efforts. These initiatives are expected to result in a broader and higher-value product mix, contributing to sustainable organic growth and enhanced pricing power.
AI Analysis | Feedback
Share Repurchases
- Merit Medical Systems did not repurchase any shares during the years ended December 31, 2024, 2023, and 2022.
Share Issuance
- In 2025, financing activities for Merit Medical Systems included $16.0 million in proceeds from the issuance of common stock.
- The company's weighted average share count for 2026 guidance assumes an incremental dilution of approximately 500,000 shares related to its convertible debt facility.
Outbound Investments
- In 2025, Merit Medical Systems completed the acquisition of Biolife Delaware, L.L.C. This acquisition was for $120 million, closing on May 20, 2025.
- The company also acquired the C2 CryoBalloon device from Pentax of America, Inc. in 2025, finalizing the acquisition on November 3, 2025.
- On November 1, 2024, Merit Medical completed the acquisition of Cook Medical's lead management portfolio for approximately $210 million in cash.
Capital Expenditures
- Merit Medical Systems' capital expenditures were $81.7 million in 2025.
- A significant portion of the cash used in investing activities in 2025, totaling $247.4 million, was allocated to acquisitions and capital expenditures, including the construction of a new distribution facility in South Jordan, Utah.
- For 2026, the company anticipates spending approximately $80 million to $100 million on property and equipment.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 90.90 |
| Mkt Cap | 40.5 |
| Rev LTM | 11,313 |
| Op Inc LTM | 2,305 |
| FCF LTM | 1,067 |
| FCF 3Y Avg | 1,304 |
| CFO LTM | 2,466 |
| CFO 3Y Avg | 2,151 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.8% |
| Rev Chg 3Y Avg | 5.1% |
| Rev Chg Q | 9.7% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | 5.8% |
| Op Inc Chg 3Y Avg | 6.2% |
| Op Mgn LTM | 14.3% |
| Op Mgn 3Y Avg | 14.4% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 20.7% |
| CFO/Rev 3Y Avg | 20.6% |
| FCF/Rev LTM | 13.8% |
| FCF/Rev 3Y Avg | 14.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 40.5 |
| P/S | 3.5 |
| P/Op Inc | 21.5 |
| P/EBIT | 17.4 |
| P/E | 22.3 |
| P/CFO | 17.9 |
| Total Yield | 3.8% |
| Dividend Yield | 0.5% |
| FCF Yield 3Y Avg | 3.8% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 16.0% |
| 3M Rtn | 25.1% |
| 6M Rtn | 4.9% |
| 12M Rtn | 4.7% |
| 3Y Rtn | 15.4% |
| 1M Excs Rtn | 14.5% |
| 3M Excs Rtn | 24.0% |
| 6M Excs Rtn | -4.5% |
| 12M Excs Rtn | -17.3% |
| 3Y Excs Rtn | -58.8% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cardiovascular | 1,443 | 1,302 | 1,221 | 1,118 | 1,043 |
| Endoscopy | 73 | 55 | 37 | 33 | 32 |
| Total | 1,516 | 1,357 | 1,257 | 1,151 | 1,075 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cardiovascular | 166 | 150 | 114 | 81 | 53 |
| Endoscopy | 19 | 6 | 10 | 7 | 8 |
| Total | 185 | 156 | 124 | 88 | 61 |
| $ Mil | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cardiovascular | 2,308 | 1,652 | 1,636 | 1,655 | 1,745 |
| Endoscopy | 17 | 12 | 13 | 10 | 12 |
| Total | 2,325 | 1,664 | 1,648 | 1,664 | 1,757 |
Price Behavior
| Market Price | $91.11 | |
| Market Cap ($ Bil) | 5.4 | |
| First Trading Date | 02/26/1992 | |
| Distance from 52W High | -2.2% | |
| 50 Days | 200 Days | |
| DMA Price | $73.04 | $76.25 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 24.7% | 19.5% |
| 3M | 1YR | |
| Volatility | 29.4% | 30.5% |
| Downside Capture | -82.76 | 36.46 |
| Upside Capture | 106.46 | 37.21 |
| Correlation (SPY) | 4.3% | 20.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.21 | -0.01 | -0.02 | 0.48 | 0.48 | 0.72 |
| Up Beta | -0.04 | -0.69 | 0.20 | 0.66 | 0.93 | 0.89 |
| Down Beta | -0.34 | 0.09 | 0.19 | 0.27 | 0.34 | 0.68 |
| Up Capture | 210% | 122% | 35% | 43% | 25% | 28% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 15 | 26 | 36 | 60 | 124 | 383 |
| Down Capture | -121% | -87% | -84% | 49% | 48% | 87% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 6 | 16 | 25 | 64 | 125 | 365 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MMSI | |
|---|---|---|---|---|
| MMSI | 6.5% | 30.5% | 0.22 | - |
| Sector ETF (XLV) | 30.9% | 15.5% | 1.53 | 44.1% |
| Equity (SPY) | 22.1% | 12.8% | 1.28 | 20.6% |
| Gold (GLD) | 28.2% | 28.4% | 0.86 | 5.7% |
| Commodities (DBC) | 37.4% | 20.1% | 1.47 | -16.5% |
| Real Estate (VNQ) | 12.5% | 13.8% | 0.61 | 37.9% |
| Bitcoin (BTCUSD) | -45.3% | 42.9% | -1.28 | 5.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MMSI | |
|---|---|---|---|---|
| MMSI | 6.7% | 29.7% | 0.24 | - |
| Sector ETF (XLV) | 6.2% | 15.0% | 0.23 | 46.5% |
| Equity (SPY) | 13.3% | 17.2% | 0.60 | 47.0% |
| Gold (GLD) | 18.8% | 18.6% | 0.82 | 8.9% |
| Commodities (DBC) | 9.3% | 19.6% | 0.36 | 4.9% |
| Real Estate (VNQ) | 1.9% | 18.9% | -0.00 | 43.9% |
| Bitcoin (BTCUSD) | 10.9% | 52.8% | 0.39 | 18.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MMSI | |
|---|---|---|---|---|
| MMSI | 14.8% | 36.3% | 0.49 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 46.4% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | 47.6% |
| Gold (GLD) | 12.0% | 16.2% | 0.61 | 4.2% |
| Commodities (DBC) | 7.9% | 18.0% | 0.35 | 12.7% |
| Real Estate (VNQ) | 4.5% | 20.7% | 0.18 | 43.5% |
| Bitcoin (BTCUSD) | 59.4% | 66.1% | 0.99 | 13.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/30/2026 | 2.0% | 5.2% | |
| 4/30/2026 | -9.0% | -8.6% | -9.0% |
| 2/24/2026 | -3.9% | -9.2% | -17.4% |
| 1/8/2026 | -7.3% | -13.8% | -13.3% |
| 10/30/2025 | 5.4% | 4.2% | 1.6% |
| 7/30/2025 | 2.3% | 0.7% | 8.5% |
| 5/20/2025 | -2.3% | -4.4% | -6.9% |
| 2/25/2025 | -1.5% | -0.1% | 1.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 15 | 16 | 14 |
| # Negative | 10 | 9 | 10 |
| Median Positive | 4.0% | 4.8% | 9.1% |
| Median Negative | -3.4% | -6.6% | -6.2% |
| Max Positive | 9.3% | 11.2% | 18.0% |
| Max Negative | -11.1% | -13.8% | -17.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/30/2026 | 2.0% | 5.2% | |
| 4/30/2026 | -9.0% | -8.6% | -9.0% |
| 2/24/2026 | -3.9% | -9.2% | -17.4% |
| 1/8/2026 | -7.3% | -13.8% | -13.3% |
| 10/30/2025 | 5.4% | 4.2% | 1.6% |
| 7/30/2025 | 2.3% | 0.7% | 8.5% |
| 5/20/2025 | -2.3% | -4.4% | -6.9% |
| 2/25/2025 | -1.5% | -0.1% | 1.6% |
| 10/30/2024 | 4.0% | 8.0% | 9.5% |
| 8/1/2024 | 5.5% | 8.0% | 14.9% |
| 4/30/2024 | 3.4% | 8.6% | 9.2% |
| 2/28/2024 | -4.9% | -6.6% | -5.5% |
| 1/8/2024 | 3.3% | 4.8% | 4.3% |
| 10/26/2023 | 8.7% | 11.2% | 13.0% |
| 7/25/2023 | -11.1% | -9.2% | -15.2% |
| 6/8/2023 | -0.7% | -2.5% | -2.4% |
| 2/22/2023 | 3.7% | 0.4% | 3.0% |
| 10/26/2022 | 5.6% | 9.2% | 18.0% |
| 7/27/2022 | 1.6% | 4.6% | 9.0% |
| 2/24/2022 | 9.3% | 9.2% | 5.8% |
| 10/28/2021 | -0.6% | 0.7% | -4.7% |
| 7/29/2021 | 8.0% | 3.2% | 10.4% |
| 4/29/2021 | 0.5% | 2.4% | -4.7% |
| 2/24/2021 | -2.9% | -2.9% | -2.2% |
| 10/28/2020 | 4.8% | 4.8% | 11.3% |
| SUMMARY STATS | |||
| # Positive | 15 | 16 | 14 |
| # Negative | 10 | 9 | 10 |
| Median Positive | 4.0% | 4.8% | 9.1% |
| Median Negative | -3.4% | -6.6% | -6.2% |
| Max Positive | 9.3% | 11.2% | 18.0% |
| Max Negative | -11.1% | -13.8% | -17.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/30/2026 | 10-Q |
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/24/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 10/28/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/30/2026 | 10-Q |
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/24/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 10/28/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 03/01/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 03/01/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 03/02/2020 | 10-K |
| 09/30/2019 | 11/08/2019 | 10-Q |
Recent Forward Guidance
Updated 7/31/2026Latest: Q2 2026 Earnings Reported 7/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | 1.63 Bil | 1.64 Bil | 1.64 Bil | 0.9% | Raised | Guidance: 1.62 Bil for 2026 | |
| 2026 Non-GAAP Earnings Per Share | 4.25 | 4.3 | 4.35 | 5.4% | Raised | Guidance: 4.08 for 2026 | |
| 2026 Revenue Growth | 6.0% | 8.0% | |||||
| 2026 Non-GAAP Earnings Per Share Growth | 5.0% | 8.0% | |||||
Prior: Q1 2026 Earnings Reported 4/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | 1.61 Bil | 1.62 Bil | 1.63 Bil | 0.2% | Raised | Guidance: 1.62 Bil for 2026 | |
| 2026 Revenue Growth | 6.0% | 7.0% | 8.0% | ||||
| 2026 Non-GAAP Earnings Per Share | 4.01 | 4.08 | 4.15 | 0 | Affirmed | Guidance: 4.08 for 2026 | |
| 2026 Non-GAAP Earnings Per Share Growth | 5.0% | 6.5% | 8.0% | ||||
Insider Activity
Updated 8/5/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peterson, Neil W | CHIEF OPERATING OFFICER | Direct | Sell | 8052026 | 85.00 | 21,449 | 1,823,165 | 2,171,835 | Form |
| 2 | Smith, Christian Adam | Chief Commercial Officer | 401(k) Plan | Buy | 5132026 | 61.00 | 1,626 | 99,186 | 135,420 | Form |
| 3 | Ward, Lynne N | Direct | Sell | 5112026 | 62.61 | 5,000 | 313,035 | 488,898 | Form | |
| 4 | Lloyd, Brian G | CHIEF LEGAL OFFICER, SECRETARY | 401 (k) plan | Buy | 5112026 | 62.62 | 2,000 | 125,250 | 125,250 | Form |
| 5 | Parra, Raul JR | CFO AND TREASURER | Direct | Buy | 5072026 | 61.01 | 1,500 | 91,515 | 3,590,011 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peterson, Neil W | CHIEF OPERATING OFFICER | Direct | Sell | 8052026 | 85.00 | 21,449 | 1,823,165 | 2,171,835 | Form |
| 2 | Smith, Christian Adam | Chief Commercial Officer | 401(k) Plan | Buy | 5132026 | 61.00 | 1,626 | 99,186 | 135,420 | Form |
| 3 | Ward, Lynne N | Direct | Sell | 5112026 | 62.61 | 5,000 | 313,035 | 488,898 | Form | |
| 4 | Lloyd, Brian G | CHIEF LEGAL OFFICER, SECRETARY | 401 (k) plan | Buy | 5112026 | 62.62 | 2,000 | 125,250 | 125,250 | Form |
| 5 | Parra, Raul JR | CFO AND TREASURER | Direct | Buy | 5072026 | 61.01 | 1,500 | 91,515 | 3,590,011 | Form |
| 6 | Aronson, Martha Goldberg | President and CEO | Direct | Buy | 5072026 | 60.44 | 2,000 | 120,880 | 3,009,428 | Form |
| 7 | Voigt, Michel J | CHIEF HUMAN RESOURCES OFFICER | 401(k) Plan | Buy | 5072026 | 60.65 | 2,250 | 136,462 | 137,372 | Form |
| 8 | Lampropoulos, Fred P | Executive Chairman | Direct | Sell | 11262025 | 88.04 | 10,000 | 880,377 | 89,794,492 | Form |
| 9 | Lampropoulos, Fred P | Executive Chairman | Direct | Sell | 11242025 | 87.31 | 25,000 | 2,182,750 | 89,925,371 | Form |
| 10 | Lampropoulos, Fred P | Executive Chairman | Direct | Sell | 11212025 | 85.13 | 20,000 | 1,702,650 | 89,810,957 | Form |
| 11 | Lampropoulos, Fred P | Executive Chairman | Direct | Sell | 11202025 | 84.83 | 5,000 | 424,130 | 91,184,133 | Form |
| 12 | Ward, Lynne N | Direct | Sell | 8252025 | 88.56 | 3,000 | 265,680 | 1,134,365 | Form | |
| 13 | Ward, Lynne N | Direct | Sell | 8122025 | 84.89 | 2,433 | 206,536 | 1,087,348 | Form |
Investor Activity (13F)
Updated Aug 12, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Iron Triangle Partners LP | $34.0 Mil | 3.9% | 27 | Exited | 13F |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.